A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)

Clinical trial NCT02784002 · COMPLETED

Trial details

NCT number: NCT02784002
Sponsor: Summit Therapeutics
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Clostridium Difficile Infection

Start date: 2014-12-01
Primary completion: 2016-08-01
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.